{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:44:29Z","timestamp":1792125869630,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI1500711"],"award-info":[{"award-number":["PI1500711"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI1200260"],"award-info":[{"award-number":["PI1200260"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CIBERONC-CB16\/12\/00231"],"award-info":[{"award-number":["CIBERONC-CB16\/12\/00231"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI18\/00573"],"award-info":[{"award-number":["PI18\/00573"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00c3\u00b3 la Marat\u00c3\u00b3 de TV3","doi-asserted-by":"publisher","award":["FMTV 201331-31"],"award-info":[{"award-number":["FMTV 201331-31"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2017\/SGR1368"],"award-info":[{"award-number":["2017\/SGR1368"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00c3\u00b3n Cient\u00c3\u00adfica Asociaci\u00c3\u00b3n Espa\u00c3\u00b1ola Contra el C\u00c3\u00a1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jid.2019.11.014","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T11:20:10Z","timestamp":1577100010000},"page":"1253-1265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5642-5620","authenticated-orcid":false,"given":"Carla","family":"Barcel\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3079-1793","authenticated-orcid":false,"given":"Pol","family":"Sis\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-4388","authenticated-orcid":false,"given":"Oscar","family":"Maiques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4931-1267","authenticated-orcid":false,"given":"Sandra","family":"Garc\u00eda-Mulero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-3527","authenticated-orcid":false,"given":"Rebeca","family":"Sanz-Pamplona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1622-5311","authenticated-orcid":false,"given":"Ra\u00fal","family":"Navaridas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-6745","authenticated-orcid":false,"given":"Cristina","family":"Megino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6852-7322","authenticated-orcid":false,"given":"Isidre","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1261-3181","authenticated-orcid":false,"given":"Izaskun","family":"Urdanibia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2131-7915","authenticated-orcid":false,"given":"N\u00faria","family":"Eritja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5644-1214","authenticated-orcid":false,"given":"Xavier","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3606-1724","authenticated-orcid":false,"given":"Josep M.","family":"Piulats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-4018","authenticated-orcid":false,"given":"Rosa M.","family":"Penin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-0449","authenticated-orcid":false,"given":"Xavier","family":"Dolcet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-6605","authenticated-orcid":false,"given":"Xavier","family":"Mat\u00edas-Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6866-6114","authenticated-orcid":false,"given":"Rosa M.","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6038-178X","authenticated-orcid":false,"given":"Anna","family":"Maci\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2019.11.014_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13073-017-0431-3","article-title":"Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy","volume":"9","author":"Ahronian","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.jid.2019.11.014_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/cancers11020134","article-title":"T-type calcium channels in cancer","volume":"11","author":"Antal","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2019.11.014_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/atm.2017.06.09","article-title":"Overcoming resistance to BRAF inhibitors","volume":"5","author":"Arozarena","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jid.2019.11.014_bib4","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2019.11.014_bib5","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-14-1027","article-title":"Complete loss of PTEN protein expression correlates with Shorter Time to brain metastasis and survival in stage IIIB\/C melanoma patients with BRAFV600 mutations","volume":"20","author":"Bucheit","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2019.11.014_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/cancers9050048","article-title":"Targeting intracellular calcium signaling ([Ca2+]i) to overcome acquired multidrug resistance of cancer cells: a mini-overview","volume":"9","author":"B\u00fcsselberg","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2019.11.014_bib7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nature03918","article-title":"Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis","volume":"436","author":"Chen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jid.2019.11.014_bib8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/cdd.2014.183","article-title":"Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma","volume":"22","author":"Corazzari","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jid.2019.11.014_bib9","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.356","article-title":"BRAF V600E cooperates with PTEN silencing to elicit metastatic melanoma","volume":"41","author":"Dankort","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2019.11.014_bib10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1755-148X.2012.00978.x","article-title":"Functional expression of voltage-gated calcium channels in human melanoma","volume":"25","author":"Das","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jid.2019.11.014_bib11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/pcmr.12155","article-title":"T-type calcium channel blockers inhibit autophagy and promote apoptosis of malignant melanoma cells","volume":"26","author":"Das","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jid.2019.11.014_bib12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jid.2019.11.014_bib13","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jid.2019.11.014_bib14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00424-014-1444-z","article-title":"T-type calcium channels blockers as new tools in cancer therapies","volume":"466","author":"Dziegielewska","year":"2014","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.jid.2019.11.014_bib15","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/15548627.2016.1271512","article-title":"Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer","volume":"13","author":"Eritja","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.jid.2019.11.014_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2019.11.014_bib17","doi-asserted-by":"crossref","first-page":"856","DOI":"10.15252\/embj.201490784","article-title":"Autophagy in malignant transformation and cancer progression","volume":"34","author":"Galluzzi","year":"2015","journal-title":"EMBO J"},{"key":"10.1016\/j.jid.2019.11.014_bib18","doi-asserted-by":"crossref","first-page":"djt435","DOI":"10.1093\/jnci\/djt435","article-title":"Genetic alterations and personalized medicine in melanoma: progress and future prospects","volume":"106","author":"Griewank","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jid.2019.11.014_bib19","doi-asserted-by":"crossref","first-page":"2301s","DOI":"10.1158\/1078-0432.CCR-05-2518","article-title":"Genetic alterations in signaling pathways in melanoma","volume":"12","author":"Haluska","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2019.11.014_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2014.12.050","article-title":"Advances in targeted therapy for unresectable melanoma: new drugs and combinations","volume":"359","author":"Hao","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jid.2019.11.014_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-17-0682","article-title":"Exploiting drug addiction mechanisms to select against mapki-resistant melanoma","volume":"8","author":"Hong","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2019.11.014_bib22","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2019.11.014_bib23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4161\/auto.19496","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy","volume":"8","author":"Klionsky","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.jid.2019.11.014_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1947601910373795","article-title":"The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-\u03baB\/snail\/RKIP\/PTEN circuit","volume":"1","author":"Lin","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.jid.2019.11.014_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11523-018-0565-2","article-title":"The role of autophagy in the resistance to BRAF inhibition in BRAF-mutated melanoma","volume":"13","author":"Liu","year":"2018","journal-title":"Target Oncol"},{"key":"10.1016\/j.jid.2019.11.014_bib26","first-page":"3585","article-title":"Resveratrol overcomes cellular resistance to vemurafenib through dephosphorylation of AKT in BRAF-mutated melanoma cells","volume":"36","author":"Luo","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jid.2019.11.014_bib27","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1172\/JCI70454","article-title":"Targeting ER stress\u2013induced autophagy overcomes BRAF inhibitor resistance in melanoma","volume":"124","author":"Ma","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2019.11.014_bib28","doi-asserted-by":"crossref","first-page":"587135","DOI":"10.1155\/2015\/587135","article-title":"Calcium channel expression and applicability as targeted therapies in melanoma","volume":"2015","author":"Maci\u00e0","year":"2015","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jid.2019.11.014_bib29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/cancers2020989","article-title":"Prognostic significance of melanoma differentiation and trans-differentiation","volume":"2","author":"Maddodi","year":"2010","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2019.11.014_bib30","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/pcmr.12690","article-title":"T-type calcium channels drive migration\/invasion in BRAFV600E melanoma cells through Snail 1","volume":"31","author":"Maiques","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jid.2019.11.014_bib31","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/bjd.15121","article-title":"Immunohistochemical analysis of T-type calcium channels in acquired melanocytic nevi and melanoma","volume":"176","author":"Maiques","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2019.11.014_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21037\/atm.2016.06.07","article-title":"Resistant mechanisms to BRAF inhibitors in melanoma","volume":"4","author":"Manzano","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jid.2019.11.014_bib33","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1080\/15548627.2017.1332550","article-title":"An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAFV600E inhibitor-resistant metastatic melanoma cells","volume":"13","author":"Martin","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.jid.2019.11.014_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bcp.2014.12.003","article-title":"Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in vemurafenib-resistant melanoma cells","volume":"93","author":"Martin","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jid.2019.11.014_bib35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/1440-1681.12436","article-title":"ER stress-induced autophagy in melanoma","volume":"42","author":"Meng","year":"2015","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jid.2019.11.014_bib36","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"M\u00fcller","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2019.11.014_bib37","first-page":"5941","article-title":"New drug combination strategies in melanoma: current status and future directions","volume":"37","author":"Najem","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jid.2019.11.014_bib38","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jid.2019.11.014_bib39","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jid.2019.11.014_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1479-5876-8-39","article-title":"Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032","volume":"8","author":"S\u00f8ndergaard","year":"2010","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jid.2019.11.014_bib41","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2019.11.014_bib42","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.18632\/oncotarget.2602","article-title":"Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma","volume":"5","author":"Spagnolo","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2019.11.014_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.350","article-title":"Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment","volume":"4","author":"Sui","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jid.2019.11.014_bib44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jid.2019.11.014_bib45","first-page":"28","article-title":"Melanoma: genetic abnormalities, tumor progression, clonal evolution and tumor initiating cells","volume":"5","author":"Testa","year":"2017","journal-title":"Med Sci"},{"key":"10.1016\/j.jid.2019.11.014_bib46","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","article-title":"Management of cutaneous melanoma","volume":"351","author":"Tsao","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2019.11.014_bib47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2159-8290.CD-13-0631","article-title":"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF\/MEK inhibition","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2019.11.014_bib48","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/sj.onc.1206451","article-title":"PTEN signaling pathways in melanoma","volume":"22","author":"Wu","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2019.11.014_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1042\/bse0550105","article-title":"Autophagy and cell death","volume":"55","author":"Yonekawa","year":"2013","journal-title":"Essays Biochem"},{"key":"10.1016\/j.jid.2019.11.014_bib50","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-16-2347","article-title":"Targetable T-type calcium channels drive glioblastoma","volume":"77","author":"Zhang","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2019.11.014_bib51","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/JTO.0b013e31828c7210","article-title":"The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib","volume":"8","author":"Zou","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jid.2019.11.014_bib52","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1038\/s41388-018-0205-4","article-title":"AXL\/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma","volume":"37","author":"Zuo","year":"2018","journal-title":"Oncogene"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X19334979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X19334979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:45:16Z","timestamp":1762206316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X19334979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0022202X19334979"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2019.11.014","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2019.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}